Magrolimab + azacitidine versus azacitidine + placebo in untreated higher risk myelodysplastic syndrome: the Phase 3, randomized, ENHANCE Study

Magrolimab + azacitidine versus azacitidine + placebo in untreated higher risk myelodysplastic syndrome: the Phase 3, randomized, ENHANCE Study

Bibliographic Details
Main Authors: Garcia-Manero, G, Daver, N, Xu, J, Chao, M, Chung, T, Tan, A, Wang, Y, Wei, A, Vyas, P, Sallman, D
Format: Conference item
Language:English
Published: Wiley 2021

Similar Items